Bull Flag Stocks
AGIO is forming a bull flag pattern, suggesting a potential continuation of its upward trend.
AGIOS PHARMACEUTICALS INC (AGIO) Stock Price & Overview
NASDAQ:AGIO • US00847X1046
Current stock price
32.92 USD
0 (0%)
At close:
32.92 USD
0 (0%)
After Hours:
The current stock price of AGIO is 32.92 USD. Today AGIO is down by 0%. In the past month the price increased by 19.32%. In the past year, price increased by 23.3%.
AGIO Key Statistics
52-Week Range22.24 - 46
Current AGIO stock price positioned within its 52-week range.
1-Month Range27.26 - 36.35
Current AGIO stock price positioned within its 1-month range.
- Market Cap
- 1.929B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -7.12
- Dividend Yield
- N/A
AGIO Stock Performance
Today
0%
1 Week
-6.48%
1 Month
+19.32%
3 Months
+15.87%
Longer-term
6 Months -18.94%
1 Year +23.30%
2 Years +1.29%
3 Years +43.94%
5 Years -41.00%
10 Years -32.75%
AGIO Stock Chart
AGIO Stock Screens
AGIO currently appears in the following ChartMill screener lists.
AGIO Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to AGIO. When comparing the yearly performance of all stocks, AGIO is one of the better performing stocks in the market, outperforming 73.01% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
AGIO Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AGIO. AGIO has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AGIO Earnings
On February 12, 2026 AGIO reported an EPS of -1.86 and a revenue of 20.00M. The company beat EPS expectations (6.31% surprise) and beat revenue expectations (63.21% surprise).
Next Earnings DateApr 30, 2026
Last Earnings DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported-$1.86
Revenue Reported20M
EPS Surprise 6.31%
Revenue Surprise 63.21%
AGIO Forecast & Estimates
16 analysts have analysed AGIO and the average price target is 41.97 USD. This implies a price increase of 27.48% is expected in the next year compared to the current price of 32.92.
For the next year, analysts expect an EPS growth of 5.34% and a revenue growth 102.6% for AGIO
Analysts
Analysts81.25
Price Target41.97 (27.49%)
EPS Next Y5.34%
Revenue Next Year102.6%
AGIO Groups
Sector & Classification
AGIO Financial Highlights
Over the last trailing twelve months AGIO reported a non-GAAP Earnings per Share(EPS) of -7.12. The EPS decreased by -1.77% compared to the year before.
Income Statements
Revenue(TTM)54.03M
Net Income(TTM)-412.78M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.82% | ||
| ROE | -34.6% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-29.17%
Sales Q2Q%86.39%
EPS 1Y (TTM)-1.77%
Revenue 1Y (TTM)48.03%
AGIO Ownership
Ownership
Inst Owners103.24%
Shares58.59M
Float55.68M
Ins Owners0.93%
Short Float %11.12%
Short Ratio7.29
AGIO Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.01 | 375.559B | ||
| AMGN | AMGEN INC | 15.38 | 191.693B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 176.393B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.5 | 113.496B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.02 | 81.177B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.17 | 42.608B | ||
| INSM | INSMED INC | N/A | 34.4B | ||
| NTRA | NATERA INC | N/A | 28.771B | ||
| BIIB | BIOGEN INC | 10.76 | 25.993B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.14 | 25.192B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| INCY | INCYTE CORP | 12.54 | 19.296B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.068B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AGIO
Company Profile
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. The company is headquartered in Cambridge, Massachusetts and currently employs 539 full-time employees. The company went IPO on 2013-07-24. The firm is focused on developing and delivering transformative therapies for patients living with rare diseases. The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. The company is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Company Info
IPO: 2013-07-24
AGIOS PHARMACEUTICALS INC
88 Sidney Street
Cambridge MASSACHUSETTS 02139 US
CEO: Jacqualyn A. Fouse
Employees: 539
Phone: 16176498600
AGIOS PHARMACEUTICALS INC / AGIO FAQ
What does AGIOS PHARMACEUTICALS INC do?
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. The company is headquartered in Cambridge, Massachusetts and currently employs 539 full-time employees. The company went IPO on 2013-07-24. The firm is focused on developing and delivering transformative therapies for patients living with rare diseases. The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. The company is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
What is the stock price of AGIOS PHARMACEUTICALS INC today?
The current stock price of AGIO is 32.92 USD.
Does AGIO stock pay dividends?
AGIO does not pay a dividend.
How is the ChartMill rating for AGIOS PHARMACEUTICALS INC?
AGIO has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Is AGIOS PHARMACEUTICALS INC (AGIO) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AGIO.
What is the market capitalization of AGIO stock?
AGIOS PHARMACEUTICALS INC (AGIO) has a market capitalization of 1.93B USD. This makes AGIO a Small Cap stock.
Can you provide the upcoming earnings date for AGIOS PHARMACEUTICALS INC?
AGIOS PHARMACEUTICALS INC (AGIO) will report earnings on 2026-04-30.